To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
Phase 2
Completed
- Conditions
- Worsening Heart Failure (WHF)Heart Failure
- Interventions
- Drug: R2R01Drug: Placebo
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 33
- Registration Number
- NCT06264310
- Locations
- ๐บ๐ธ
California Pacific Medical Center, San Francisco, California, United States
๐บ๐ธPiedmont Hospital Transplant, Atlanta, Georgia, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Phase 2
Recruiting
- Conditions
- Hepatorenal SyndromeAcute Kidney Injury
- Interventions
- Drug: R2R01Drug: Terlipressin
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 95
- Registration Number
- NCT05875948
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธBaylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States
๐บ๐ธCalifornia Pacific Medical Center, San Francisco, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath